ZLB Behring’s Vivaglobin Is First Patient-Administered Immunoglobulin Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s approval of the subcutaneous IG replacement therapy provides an alternative to intravenous treatment of primary immune deficiency.